FDA investigates the cancer risk of angiotensin-receptor blockers

07/15/2010 | Reuters

FDA officials are investigating angiotensin-receptor blockers, a class of blood pressure drugs, after clinical data suggested that they might increase the risk of cancer. However, the agency thinks "the benefits of ARBs continue to outweigh their potential risks."

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX